<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342952</url>
  </required_header>
  <id_info>
    <org_study_id>114588</org_study_id>
    <nct_id>NCT01342952</nct_id>
  </id_info>
  <brief_title>Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529</brief_title>
  <official_title>An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, long term extension to Study AMB112529. All subjects may remain in the
      extension study for a minimum of six months. Beyond the six month period, subjects may
      continue in the extension study until one of the following conditions is met:

      the subject turns 18 years of age (when the subject can receive marketed product) the product
      is approved and available for use in the subject's age group, development for use in the
      paediatric population is discontinued. the subject decides he/she no longer wants to
      participate in the study, the investigator considers it is in the best interest of the
      subject to discontinue ambrisentan (e.g. for safety reasons).

      The primary objective is the long-term safety and tolerability of ambrisentan in the
      paediatric PAH population. Secondary objectives are all cause mortality and change from
      baseline in Study AMB112529 on efficacy parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) is a rare, progressive, highly debilitating disease
      characterized by vascular obstruction and the variable presence of vasoconstriction, leading
      to increased pulmonary vascular resistance and right-sided heart failure. If left untreated,
      PAH ultimately leads to right ventricular failure and death; adult subjects have a median
      survival of 2.8 years without treatment. Epidemiological estimates vary but prevalence in
      Europe is thought to be of the order of 15 cases per million. Large scale epidemiology
      studies of PAH in children have not been conducted and there is no or limited outcome data in
      paediatric PAH patients. A register in France (1995-1996) estimates the prevalence in
      children is as low as 3.7 cases per million. In a national, comprehensive country wide survey
      of the epidemiology of idiopathic PAH (IPAH) management and survival in the United Kingdom
      (UK) the incidence was 0.48 cases per million children per year and the prevalence was 2.1
      cases per million children.

      Ambrisentan (VOLIBRIS™ tablets) is an endothelin receptor antagonist (ERA) marketed in the
      European Union (EU) and some other countries by GlaxoSmithKline (GSK) and in the United
      States as LETAIRIS® by Gilead Sciences Inc. Ambrisentan is indicated for the treatment of
      adult patients with PAH to improve exercise capacity, decrease the symptoms of PAH, and delay
      clinical worsening.

      The primary purpose of this long term paediatric study is to provide clinically relevant
      information on the long term safety of ambrisentan in children with the most common causes of
      PAH in this age group. This study is only open to patients who have participated in Study
      AMB112529, A randomized, open label study comparing safety and efficacy parameters for a high
      and a low dose of ambrisentan (adjusted for body weight) for the treatment of pulmonary
      arterial hypertension in paediatric patients aged 8 years up to 18 years, and in whom
      continued treatment with ambrisentan is warranted.

      This study is part of a Paediatric Investigational Plan (PIP; EMEA-000434-PIP01-08) agreed
      with the European Medicines Agency's Paediatric Committee (PDCO).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 1, 2011</start_date>
  <completion_date type="Anticipated">October 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 27, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Number of patients with a serious adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Number of patients with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Function Tests</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>AST, ALT, GGT, and total bilirubin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Chemistries</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>sodium, magnesium, potassium, calcium, glucose, chloride, bicarbonate, phosphorus-inorganic, creatinine, total protein, albumin, LDH, creatine phosphokinase, blood urea nitrogen, uric acid, and alkaline phosphatase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haematology</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>platelet count, RBC count, reticulocyte count, hematocrit, hemoglobin, RBC indices (MVC, MCH, and MCHC), WBC count, and automated WBC differential</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Change from baseline from Study AMB112529 in physical parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Change from baseline from Study AMB112529 in blood pressure, respiratory rate, and heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Change from baseline from Study AMB112529</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endocrinology assessments</measure>
    <time_frame>up to 20 years of age</time_frame>
    <description>FSH, LH, sex hormone binding globulin, inhibin B, testosterone (males only) and estrogen (females only)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pubertal Development</measure>
    <time_frame>up to 20 years of age</time_frame>
    <description>Assessed using Tanner criteria. Testicular volume will be estimated in males using Prader's orchidometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Change from baseline from study AMB112529 in the distance walked in six minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO functional class</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Change from baseline from study AMB112529 i nWHO functional class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health outcomes assessments</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Change from baseline from study AMB112529 in SF 10 and the proportion of days missed from school due to symptoms of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Pericardial effusion, right atrial pressure, tricuspid annular plane systolic excursion, eccentricity index (systolic and diastolic), and right ventricular pressure by tricuspid regurgitant jet velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma NT-Pro-BNP</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>Change from baseline from study AMB112529 in plasma NT-Pro BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening</measure>
    <time_frame>up to 18 years of age</time_frame>
    <description>The time from randomization in study AMB112529 until the first occurence of: death (all cause) or placed on active list for lung transplant; hospitalisation due to PAH deterioration; addition or increased dose of other targeted PAH therapeutic agents (prostanoids, PDE-5 inhibitors) due to deterioration of clinical condition; atrial septostomy; or PAH related deterioration (increase in WHO functional class, deterioration in exercise testing, clinical signs of symptoms of right sided heart failure)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Ambrisentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, flexible dosing from 2.5 mg to 10 mg (not to exceed 0.25 mg/kg) per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambrisentan</intervention_name>
    <description>open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day</description>
    <arm_group_label>Ambrisentan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have participated in and complied, to the best of their ability, with the protocol for
             AMB112529 and have met one of the following:

               1. Completed the Week 24 visit in AMB112529;

               2. Required additional targeted treatment for PAH due to inadequate response to the
                  current treatment or worsening of their clinical condition prior to week 24 in
                  AMB112529;

               3. Required reduction in dose of baseline targeted treatment for PAH after
                  ambrisentan was added to the treatment regimen;

               4. In the opinion of the investigator, continued treatment with ambrisentan is
                  warranted.

          -  A female is eligible to participate in this study, as assessed by the investigator, if
             she is of:

               1. Non-childbearing potential (i.e., physiologically incapable of becoming
                  pregnant); or,

               2. Child-bearing potential - has a negative pregnancy test and is not lactating and,
                  if sexually active, agrees to continue to use 2 reliable methods of contraception
                  until study completion and for at least 30 days following the last dose of study
                  drug (reliable methods of contraception are listed in Appendix 2).

          -  Subject or subject's legal guardian is able and willing to give written informed
             consent. As part of the consent, female subjects of childbearing potential will be
             informed of the risk of teratogenicity and will need to be counselled in a
             developmentally appropriate manner on the importance of pregnancy prevention; and male
             subjects will need to be informed of potential risk of testicular tubular atrophy and
             aspermia.

        Exclusion Criteria:

          -  Subjects who were withdrawn from ambrisentan in Study AMB112529;

          -  Subjects who did not comply with the protocol in Study AMB112529;

          -  Female subjects who are pregnant or breastfeeding;

          -  Subjects with severe renal impairment (estimated creatinine clearance &lt;30 mL/min
             assessed within the previous 45 days) at the point of transition from Study AMB112529
             into this study;

          -  Subject with clinically significant fluid retention in the opinion of the
             investigator;

          -  Subject with clinically significant anaemia in the opinion of the investigator;

          -  Subjects who are to enter another clinical trial or be treated with another
             investigational product after exiting Study AMB112529.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-4204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guymallen</city>
        <state>Mendoza</state>
        <zip>5521</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <zip>1118</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corrientes</city>
        <zip>W3400AMZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris cedex 15</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pessac cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Donato Milanese (MI)</city>
        <state>Lombardia</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>143-8541</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Mexico</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

